Potentially, the reduction in the vascularization that accompanied this tumor transformation could be the result of the fibrotic process found during the second surgery (clinical presentation) and may be mediated by TGF-β1, a stromal fibroblast activator and inhibitor of angiogenesis (54). The gene discussed is TGFB1; the disease is neoplasm.